SDGR logo

Schrodinger Inc. (SDGR)

$25.66

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SDGR

Market cap

$1.93B

EPS

-0.78

P/E ratio

--

Price to sales

7.88

Dividend yield

--

Beta

1.693097

Price on SDGR

Previous close

$27.36

Today's open

$27.52

Day's range

$25.49 - $28.15

52 week range

$10.95 - $34

Profile about SDGR

CEO

Ramy Farid

Employees

850

Headquarters

New York, NY

Exchange

Nasdaq Global Select

Shares outstanding

75077794

Issue type

Common Stock

SDGR industries and sectors

Healthcare

Healthcare Providers & Services

News on SDGR

Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift

Schrodinger NASDAQ: SDGR is looking to its artificial intelligence assistant Bunsen and a shift toward hosted software contracts to expand use of its molecular discovery platform, executives said at the UBS Global Healthcare Conference.

news source

MarketBeat • Nov 13, 2026

news preview

Schrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript

Schrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

What Schrodinger (SDGR) Said on Its Q3 Earnings Call

Schrodinger NASDAQ: SDGR raised its full-year 2026 outlook for annual contract value and drug discovery revenue after reporting third-quarter growth in both software demand and revenue from its therapeutics collaborations.

news source

MarketBeat • Nov 5, 2026

news preview

Schrödinger Reports Third Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026. “We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each ot.

news source

Business Wire • Nov 4, 2026

news preview

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.45 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline

Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Schrödinger to Present at UBS Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference. The live presentation will take place on Tuesday, November 10, 2026 at 9:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational pl.

news source

Business Wire • Oct 28, 2026

news preview

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on October 21, 2026, the company granted restricted stock units (RSUs) with respect to 5,716 shares of the company's common stock to five newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.

news source

Business Wire • Oct 26, 2026

news preview

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform.

news source

Business Wire • Oct 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Schrodinger Inc.

Open an M1 investment account to buy and sell Schrodinger Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SDGR on M1